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The management of anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung 
cancer (NSCLC) exemplifies the potential of a precision medicine approach to cancer care. 
The ALK inhibitor crizotinib has led to improved outcomes in the first- and second-line 
setting; however, toxicities, intracranial activity, and acquired resistance necessitated the 
advent of later generation ALK inhibitors. A large portion of acquired resistance to ALK 
inhibitors is caused by secondary mutations in the ALK kinase domain. Alectinib is a 
second-generation ALK inhibitor capable of overcoming multiple crizotinib-resistant ALK 
mutations and has demonstrated improved outcomes after crizotinib failure. Favorable 
toxicity profile and improved intracranial activity have spurred ongoing front-line trials 
and comparisons to other ALK inhibitors. However, important questions regarding com-
parability to competitor compounds, acquired alectinib resistance, and ALK inhibitor 
sequencing remain. Here, we review the key clinical data supporting alectinib in the 
second-line therapy of ALK+ NSCLC and provide context in comparison to other ALK 
inhibitors in development.
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BACKGROUnD
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer and remains the leading 
cause cancer-related mortality in both men and women with a 5-year survival rate of less than 20% 
in US patients (1). Rapid advances in understanding the molecular pathogenesis of NSCLC have 
demonstrated that NSCLC is a heterogeneous group of diseases. Chromosomal rearrangements 
involving ALK and ROS1 are present in 3–7% (2) and 2% (3) of patients with NSCLC, respec-
tively. ALK translocations are found nearly exclusively in lung adenocarcinomas. Crizotinib, a 
first-generation ALK and ROS1 inhibitor, has resulted in improved progression-free survival (PFS) 
relative to chemotherapy in the first- and second-line settings for ALK-rearranged (ALK+) NSCLC. 
Compared to chemotherapy in treatment naïve ALK-rearranged patients, crizotinib led to higher 
objective response rate (ORR) (74 vs. 45%) and median PFS (10.9 vs. 7.0 months) but no differ-
ence in overall survival (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54–1.26; P = 0.36) 
(Table 1) (4). In ALK-rearranged patients with prior chemotherapy exposure, crizotinib also led to 
improved ORR (65 vs. 20%) and median PFS (7.7 vs. 3.3 months) (5). Like other oncogene driven 
TABLe 1 | Comparison of second-line therapy trials in nSCLC.
Compound Phase n Study population Primary endpoint PFS ORR Reference
ALK+ population
Ceritinib I 246 ALK+ naïve  
and crizotinib failure
RP2D 750 mg qd ALK inh naïve: 
18.4 months
ALK inh naïve: 72% (7)
ALK inh expos: 
6.9 months
ALK inh expos: 56%
Alectinib II 138 ALK+, crizotinib failure ORR 50% 8.9 months ORR 50% (8)
CNS DCR 83% among  
84 pts with CNS mets
Alectinib II 87 ALK+, crizotinib failure ORR 48% 8.1 months ORR 48% (9)
CNS DCR 100% among 
16 pts with CNS mets
Alectinib I/II 47 ALK+, crizotinib failure ORR 55% NA Overall ORR 55% (10)
CNS ORR 52%
Alectinib I 46 ALK+ naïve ORR 93.5% NA ORR 93.5% (11)
Crizotinib vs. chemo III 347 ALK+ prior chemo PFS 7.7 vs. 3.0 months 65 vs. 20% (5)
Crizotinib vs. chemo III 343 ALK+ naïve PFS 10.9 vs. 7 months 74 vs. 45% (4)
1 year survival rate 
84 vs. 79%
Unselected population
Pembrolizumab vs. docetaxel III 1,000 Unselected OS: 12.7 vs. 8.5 months 4 vs. 4 months 18 vs. 9% (12)
Nivolumab vs. docetaxel III 272 SCC OS: 9.2 vs. 6 months 1 year survival rate 
42 vs. 24%
20 vs. 9% (13)
Nivolumab vs. docetaxel III 582 Non-SCC OS: 12.2 vs. 9.4 months 1 year survival rate 
51 vs. 39%
19 vs. 12% (14)
Docetaxel + ramucirumab vs. 
docetaxel
III 1,253 Unselected pts  
after 1st line
OS: 10.5 vs. 9.1 months 4.5 vs. 3.0 months 23 vs. 14% (15)
Erlotinib vs. docetaxel or 
pemetrexed
III 424 Unselected OS: 5.3 vs. 5.5 months 1.4 vs. 2 months NA (16)




9.1 vs. 8.8% (17)
OS: 6.2 vs. 7.4 months 
in squamous
Docetaxel vs. placebo III 104 Unselected OS: 7.5 vs. 4.6 months 10.6 vs. 6.7 weeks 7.1 vs. 0% (18)
Upper portion summarizes ALK+ trials and lower portion provides findings from key second-line chemotherapy and immunotherapy trials to provide context.
2
Tran and Klempner Alectinib for Second-Line NSCLC
Frontiers in Medicine | www.frontiersin.org November 2016 | Volume 3 | Article 65
tumors, acquired resistance is nearly universal in ALK+ NSCLC, 
and most develop crizotinib resistance within 1 year of treatment 
with central nervous system (CNS) metastasis being a major site 
of progression (6).
While the propensity for intracranial failure on crizotinib 
is partly related to lower penetration of blood–brain barrier 
(19), systemic relapses are mediated by multiple mechanisms 
including secondary ALK mutations and compensatory bypass 
pathway activation. In nearly a third of patients, tumors have 
acquired secondary mutation in the ALK tyrosine kinase 
domain. The most common resistance mutation is the gate-
keeper L1196M mutation, followed by the G1269A (20–22). 
Additional resistance mutations include C1156Y, L1152R, 
G1202R, S1206Y, 1151Tins, F1174C, and D1203N, among many 
others (Table  2) (23–25). These mutations blunt the efficacy 
of crizotinib by either increasing the ALK kinase affinity for 
adenosine triphosphate (ATP) (G1269A and 1151Tins), induc-
ing conformational change causing steric hindrance (G1202R 
and S1206Y) or interfering with the downstream signaling 
pathway (L1152R) (23). Amplification of the ALK fusion gene 
was observed either alone or in combination with other resist-
ance mechanisms in both in  vitro studies (20) and resistant 
clinical specimens (26). Beyond the ALK dominant resistance 
mechanism, preclinical work and progression biopsies from 
patients on ALK inhibitors have revealed crizotinib resistance 
from amplification of epidermal growth factor receptor (EGFR) 
pathway, insulin-like growth factor pathway (IGF-1R), cKIT 
mutation, and SRC activity (26–28).
While crizotinib ushered in a new paradigm for ALK+ 
NSCLC, the emergence of acquired resistance and rates of intrac-
ranial progression suggested ongoing clinical needs in ALK+ 
disease. The management of crizotinib failure has largely been 
informed by data from later generation ALK inhibitors including 
alectinib; however, other recent second-line trials outside ALK+ 
disease are worth brief contextual mention (Table 1). The phase 
III REVEL trial demonstrated that the addition of ramucirumab 
(a vascular endothelial growth factor receptor 2 monoclonal 
antibody) to docetaxel in unselected advanced NSCLC patients 
yielded higher response rate (23 vs. 14%), median PFS (4.5 vs. 
3 months), and median OS (10.5 vs. 9.1 months) than docetaxel 
monotherapy (15). Similarly, in the phase III CheckMate 017 
trial nivolumab yielded superior ORR (20 vs. 9%), median PFS 
(3.5 vs. 2.8 months), and median OS (9.2 vs. 6.0 months) com-
pared with docetaxel in heavily pretreated unselected advanced 
squamous NSCLC patients (13). The CheckMate 057 trial found 
higher ORR (19 vs. 12%) and median OS (12.2 vs. 9.4 months) in 
TABLe 2 | Mutation coverage for ALK inhibitors in late stage clinical development.
Mutations Crizotinib Alectinib Certinib Brigatinib Lorlatinib Reference
EML4-ALK S S S S S (29, 30)
L1196M R S S S S (21, 22, 24, 29–32)
L1152P/R R S R S S (22, 30–32)
G1123S R S R NA NA (30, 33)
1151Tins R S R NA S (22, 24, 30, 31)
C1156Y R S R S S (21, 22, 29–31)
F1174V/C/L R S R S S (22, 29–31, 34)
I1171T/N/S R R S NA NA (30, 32, 35)
V1180L R R S NA NA (35)
G1202R R R R S S (22, 24, 30, 31)
G1269A/S R S S S S (22, 30–32)
F1245C R NA S NA NA (30, 36)
S1206C/Y/F R S S R S (22, 24, 30–32)
E1210K R S S S S (30)
L1198F S R R S R (30, 37)
D1203N R S S S S (30)
CMET amp S R R R R (38)
The letter S denotes mutations that are “sensitive” (clinical and/or preclinical data) to a given compound, and “R” denotes resistance. NA, data not available.
3
Tran and Klempner Alectinib for Second-Line NSCLC
Frontiers in Medicine | www.frontiersin.org November 2016 | Volume 3 | Article 65
patients with non-squamous NSCLC compared with docetaxel 
(14). The efficacy of pembrolizumab was demonstrated in phase 
II/III KEYNOTE-010 trial which compared pembrolizumab 
vs. docetaxel in more than 1,000 patients (12). Pembrolizumab 
led to improved median OS in the overall population (12.7 vs. 
8.5 months). Among 442 patients with at least 50% PD-L1 expres-
sion, the median OS for the pembrolizumab 2 mg/kg, 10 mg/kg, 
and docetaxel groups was 14.9, 17.3, and 8.2 months, respectively.
ALeCTiniB OveRview
The expanding appreciation of crizotinib-resistant ALK muta-
tions spurred development of the second-generation ALK 
inhibitors. Alectinib is a potent and selective second-generation 
oral ALK inhibitor. Alectinib exhibits limited inhibitory activity 
against other protein kinases such as EGFR, fibroblast growth 
factor receptor 2 (FGFR2), human epidermal growth factor 
receptor 2 (HER2), hepatocyte growth factor receptor (MET), 
platelet-derived growth factor subunit B (PDGFB), and Janus 
kinase 1 (JAK1) (29). In cell free assays, the half maximal inhibi-
tory concentration (IC50) of alectinib for enzyme activity of ALK 
was 1.9 nM and the dissociation constant (KD) value for ALK 
in an ATP-competitive manner was 2.4 nM (29). In vitro experi-
ments demonstrated that alectinib induces caspase-mediated 
apoptosis in EML4-ALK cell lines and results in dose-dependent 
tumor growth inhibition (ED50 = 0.46 mg/kg) and regression in 
animal models (29). More importantly, alectinib displayed sig-
nificant efficacy against crizotinib-resistant ALK L1196M (IC50, 
2 nM) and G1269A (IC50, 9 nM) mutations (22, 29). Alectinib was 
also active against ALK C1156Y, F1174L, 1151Tins, and L1152R 
but not ALK G1202R (IC50, 70–80 nM) both in vitro and in vivo 
experiments (Table 2) (22).
ALeCTininB FOR CRiZOTiniB FAiLURe
Clinical trials evaluating the safety and efficacy of alectinib 
have been conducted in Japan and the US as both first-line 
untreated and ALK+ patient progressing on crizotinib. Support 
for alectinib activity in crizotinib failure comes from the 
AF-002JG study in which alectinib at 300–900 mg BID was well 
tolerated, with the most common adverse events (AEs) being 
fatigue (30%), myalgia (17%), and peripheral edema (15%) (10). 
The recommended phase II dose was 600  mg BID. Of the 44 
evaluable patients with crizotinib resistance, 24 (55%) patients 
had response, 16 (36%) had stable disease (SD), and 4 (9%) 
had progressive disease. Alectinib also demonstrated activity 
against CNS metastases in 21 patients with an intracranial 
response rate of 52% [29% complete response (CR), 24% partial 
response (PR), and 38% SD] (10). Similar results were seen 
in a North American trial of 87 patients with advanced ALK-
rearranged NSCLC who were refractory to crizotinib (9). The 
ORR for alectinib was 48% with a median PFS of 8.1 months 
(95% CI, 6.2–12.6). Fifty two patients had brain metastases 
at enrollment and 21 (40%) patients experienced CNS tumor 
regression, including 13 (25%) patients who achieved CR. 
Alectinib 600  mg BID was well tolerated with predominantly 
low grade constipation (36%), fatigue (33%), myalgia (24%), 
and peripheral edema (23%). Finally, the large phase II global 
study (NP2873) examined the ORR of alectinib for crizotinib-
refractory ALK+ patients (n = 138) (8). This study is notable 
for a high rate of CNS metastases (61%) at baseline. The ORR 
determined by independent review committee was 50% (95% 
CI, 41–59%) and the median PFS was 8.9  months (95% CI, 
5.6–11.3). Alectinib was highly effective for CNS metastases, 
with ORR of 57% and DCR of 83%. Of the 23 patients with 
baseline untreated CNS metastases, 10 (43%) had a complete 
CNS response. The authors note that the cumulative CNS 
progression rate (24.8%) was lower than the cumulative non-
CNS progression rate (33.2%), which suggests that alectinib 
may delay or prevent the emergence of CNS metastases. 
Alectinib 600  mg BID was well tolerated with common side 
effects including low grade constipation (33%), fatigue (26%), 
and peripheral edema (25%). Overall the similar response rate 
to alectinib between the US and Japanese patients indicate 
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no ethnic difference in response. Additionally, there was no 
significant difference in alectinib exposure at 600  mg twice 
daily among a small subgroup of Caucasian and Asian patients 
who underwent pharmacokinetic analysis. Based on established 
activity, the Food and Drug Administration approved alectinib 
for the treatment of ALK+ NSCLC patients who progressed or 
were intolerant of crizotinib on December 11, 2015.
Based on promising second-line data and potential superior-
ity over crizotinib, alectinib is being investigated in the first-line 
setting. In the phase I/II AF-001JP study conducted in Japan, 
patients with ALK inhibitor-naïve ALK+ NSCLC were treated 
with alectinib (11). Alectinib at 300 mg BID daily was well toler-
ated with few grade 3 toxicities or dose-limiting toxicities (DLTs) 
and ORR was observed in 43 out of 46 patients (93.5%) at this 
dose. On the other hand, the response rate for first-line crizotinib 
reported by Solomon et al. was 74% (4). Two phase III trials, ALEX 
(NCT02075840), and JapicCTI-132316, are currently comparing 
alectinib and crizotinib in ALK inhibitor-naive patients with 
ALK-rearranged NSCLC. Recently updated clinical data among 
207 randomized patients in the J-ALEX trial were presented at 
the ASCO 2016 annual meeting (39). The primary endpoint 
was PFS and secondary endpoints included OS, ORR, CNS PFS, 
safety, and quality of life. In the alectinib arm, constipation (36%) 
was the only common event, while in the crizotinib arm nausea 
(74%), diarrhea (73%), vomiting (59%), visual disturbance (55%), 
dysgeusia (52%), constipation (46%), ALT elevation (32%), and 
AST elevation (31%) were seen in >30% patients. Alectinib was 
more tolerable than crizotinib with fewer grade 3/4 AEs (26.2 
vs. 51.9%) which translated to a lower discontinuation rate (8.7 
vs. 20.2%). The ORRs of the alectinib and crizotinib arms were 
91.6 and 78.9%, respectively. The median PFS was not reached 
(CI, 20.3 to NR) but significantly higher than crizotinib 10.2 (CI, 
8.2–12.0) with HR 0.34 (0.17–0.71). Complete data sets from 
first-line trials are eagerly awaited and may lead to additional 
indications for alectinib.
ADDiTiOnAL SeCOnD- AnD  
THiRD-GeneRATiOn ALK inHiBiTORS
The second-generation ALK inhibitor ceritinib has in vitro activ-
ity against crizotinib-resistant mutations. Results from the open 
label multicenter ASCEND-1 trial showed that ceritinib yielded 
ORR of 72% (95% CI, 61–82) in 83 ALK inhibitor-naive patients 
and 56% (49–64) in 163 ALK inhibitor-resistant patients (7). 
Median PFS was 18.4  months in ALK inhibitor-naive patients 
and 6.9 months (5.6–8.7) in ALK inhibitor-pretreated patients. 
Among 94 patients with brain metastases, intracranial disease 
control was reported in 15 of 19 (79%) ALK inhibitor-naïve 
patients and in 49 of 75 (65%) ALK inhibitor-pretreated patients. 
In ALK inhibitor-resistant patients with CNS metastasis, the rates 
of intracranial CR, PR, and SD were 5, 13, and 47%, respectively. 
Common toxicities included diarrhea (80%), nausea (77%), 
vomiting (57%), fatigue (38%), abdominal pain (37%), decreased 
appetite (36%), constipation (30%), cough (29%), abdominal 
pain (23%), and dyspnea (21%). In April 2014, ceritinib 750 mg 
daily was approved by the US FDA for ALK+ previously treated 
with crizotinib.
Although both alectinib and ceritinib have shown promising 
systemic and CNS activity they are unlikely to be compared 
head to head in clinical trials. While ceritinib appears to have 
similar systemic response to alectinib, the intracranial response 
rate appears inferior to alectinib in crizotinib-resistant patients 
with CNS metastases. Accepting cross-trial comparison caveats 
the absolute median PFS is numerically shorter for ceritinib 
(6.9 months in the ASCEND-1 trial) than alectinib (8.9 months 
in the global NP2873 trial) in ALK inhibitor-resistant patients.
Other ALK inhibitors including brigatinib (AP26113) and 
lorlatinib (PF-06463922) have shown activity in crizotinib failure 
and highlight the non-overlapping resistance mutation coverage 
among current ALK inhibitors (Table 2). Briefly, brigatinib is a 
potent dual inhibitor of ALK and EGFR, including ALK L1196M 
and EGFR T790M mutants, shown in preclinical studies (40, 41). In 
the phase II ALTA study, 222 heavily pretreated ALK-rearranged 
patients were randomized to receive brigatinib 90 mg PO (arm 
A) vs. 180  mg PO qd (arm B) (42). The investigator-assessed 
ORRs of arm A and B patients were 46% (95% CI, 36–55%) and 
54% (95% CI, 44–63%), respectively. Median PFS in arms A and 
B was 8.8 and 11.1 months, respectively. However, the median 
follow-up was only 8.3 months and longer follow-up is needed 
to confirm the higher PFS observed in arm B. Among patients 
with active brain metastases at baseline, intracranial ORRs, as 
assessed by independent review committee, in A and B were 37% 
(7/19) and 73% (11/15), respectively. Most common AEs in arms 
A/B included nausea (33/40%), diarrhea (19/38%), headache 
(28/27%), cough (18/34%), dyspnea (21/21%), fatigue (20/27%), 
constipation (19/15%), abdominal pain (17/8%), and vomiting 
(24/23%). Grade ≥  3 treatment-emergent AEs (A/B) included: 
increased CPK (3/8%), hypertension (4/5%), pneumonia (3/5%), 
rash (1/4%), and pneumonitis (2/3%). Discontinuations and dose 
reductions due to AEs (A/B) were 3/6% and 7/18%, respectively. 
Due to the favorable efficacy and toxicity profile, brigatinib 
180 mg PO daily was chosen as the optimal dose and is moving 
forward in the phase III ALTA-1L vs. crizotinib in the first-line 
setting.
Lorlatinib (PF-06463922) is a third-generation reversible, 
potent ATP-competitive small molecule, inhibitor of ALK and 
ROS1. Lorlatinib has demonstrated activity against the majority 
of known resistant ALK mutations, except for L1198F (Table 2) 
(31, 37). Early data from an ongoing phase I/II study of lorlatinib 
in mostly pretreated patients with ALK+ and ROS1+ NSCLC 
were presented at the ASCO 2016 annual meeting (43). Among 
the 54 evaluable patients who received dose escalation from 
10 mg to 200 mg, the overall response rate was 50% and intrac-
ranial response rate was 44% for target and non-target lesions 
and 60% for target lesions. The most common treatment-related 
AEs were hypercholesterolemia (54%) and peripheral edema 
(37%). Hypercholesterolemia was the most common (9%) 
grade (G) ≥  3 treatment-related AE and most frequent reason 
for dose delay/reduction. No patient was discontinued due to a 
treatment-related AEs. The phase II dose was identified as 100 mg 
once daily. Pharmacokinetic analysis of four patients revealed 
that the unbound CSF to plasma drug ratio ranged from 0.61 to 
0.96, indicative of good CSF penetration. In contrast, the ratio of 
CNS to serum concentration of crizotinib has been in the range 
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of 0.0006–0.001 in previous reports (19, 44). Lorlatinib is effective 
against the G1202R mutation (Table 2).
COnCLUSiOn/FUTURe DiReCTiOnS
Over the past decade, there has been a remarkable progress in the 
target therapy for the management of ALK-rearranged NSCLC. 
Second- and third-generation inhibitors demonstrate broader 
coverage against crizotinib-resistant ALK mutations and often 
more favorable side effect profiles. As discussed elsewhere in this 
issue, we are approaching a paradigm in which understanding 
the exact resistance mechanism will inform the optimal choice 
and perhaps sequencing of ALK inhibitors. The approval of 
alectinib for crizotinib failure highlights major areas of focus in 
ALK+ disease; toxicity profile, intracranial activity, and resistance 
mutation coverage. While alectinib compares favorably in these 
areas, ongoing results from first-line trials and direct comparison 
against current and emerging ALK inhibitors will be important 
to refine optimal alectinib usage. Here we have provided a review 
of the clinical data supporting the activity of alectinib in the 
management of ALK+ NSCLC with a focus on the second-line 
setting in advanced disease.
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